Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”

Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li

Clin Mol Hepatol. 2024;30(4):974-977. Published online July 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0417

View: 1863 Download: 80 Crossref: 1

Original Article

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):235-246. Published online January 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0485

View: 7482 Download: 314 Web of Science: 22 Crossref: 28

Correspondence

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):124-125. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0470

View: 2428 Download: 55 Web of Science: 1 Crossref: 2

Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng

Clin Mol Hepatol. 2023;29(3):823-824. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0182

View: 3526 Download: 55 Web of Science: 1 Crossref: 3

Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng

Clin Mol Hepatol. 2023;29(3):821-822. Published online May 31, 2023

DOI: https://doi.org/10.3350/cmh.2023.0183

View: 3501 Download: 76 Web of Science: 2 Crossref: 2

Original Article

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo

Clin Mol Hepatol. 2023;29(3):721-732. Published online March 22, 2023

DOI: https://doi.org/10.3350/cmh.2023.0089

View: 24918 Download: 1,675 Web of Science: 306 Crossref: 319

Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Michael H. Le, Yee Hui Yeo, Biyao Zou, Scott Barnet, Linda Henry, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2022;28(4):841-850. Published online September 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0239

View: 10635 Download: 311 Web of Science: 139 Crossref: 147

1 |

Viewed By 8320	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7305	MAFLD: How is it different from NAFLD?
Viewed By 5286	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4946	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4520	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 319	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 291	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search